Directorate Change

Synexus Clinical Research PLC
05 February 2007


                         Synexus Clinical Research plc

              Appointment of Alan Boyce as Chief Operating Officer


Synexus, the provider of Clinical Research Services for the pharmaceutical
industry, is pleased to announce that Alan Boyce has been appointed to the Board
as Chief Operating Officer with effect from 19 February.

Alan, aged 45, has previously been the Vice-President of Operations, Europe,
Middle East and Africa for the US Clinical Research Organisation, Kendle. In
this position he has successfully built the European operations of the company
into an organisation with substantial revenues, and 1300 employees across the
various countries. He led the integration in Europe of Charles River
Laboratories, acquired by Kendle.

Prior to his position with Kendle, Alan spent 18 years in the pharmaceutical
division of Procter and Gamble, working both in the UK and the USA, culminating
in the position of Commercial Director, UK and Ireland of P & G Pharmaceuticals.


Commenting on his appointment, Synexus' CEO Michael Fort said: -

"Alan brings major operational experience of both a provider of clinical
research services to the pharmaceutical industry, and of the pharma industry
itself. This expertise will be invaluable in building and integrating the
expanding operations of Synexus".


Other than as set out below, there is no additional information required to be
disclosed under Schedule 2(g) of the AIM Rules:

Alan Boyce is currently director of Kendle International Holdings Limited and
Kendle Clinical Development Services Limited. In the last five years, he was
also director of Cambrian Close Pump Management Limited.


Enquiries:

Synexus Clinical Research plc               Tel: [phone]
Michael Fort, Chief Executive

Biddicks - Financial Public Relations       Tel: [phone]
Zoe Biddick


                      This information is provided by RNS
            The company news service from the London Stock Exchange
        UUUWAPUPMGCP